Epocrates Streamlines Strategic Focus and Reports Fourth Quarter and Full Year 2011 Results

San Mateo, Calif., February 28, 2012

SAN MATEO, Calif. – February 28, 2012 – Epocrates, Inc. (NASDAQ: EPOC), a leading physician platform for clinical content, practice tools and health industry engagement, today announced a strategic streamlining of its business and reported its financial results for the fiscal fourth quarter and full year 2011.

 

"The foundational strength of Epocrates is our physician network," said Peter Brandt, Epocrates' interim president and chief executive officer. "We believe the opportunities to build upon that strength and expand beyond our current product portfolio throughout our physician network are significant and have the potential to generate meaningful revenue streams for the company. While we have developed a meaningful use certified, state‐of‐the‐art electronic health record (EHR), including a native iPad version, the effort has hindered our ability to aggressively pursue such opportunities. As a result, we are exploring strategic alternatives for our EHR offering. By focusing more on the natural extensions of our core business and providing trusted content and collaborative solutions, we have the potential to support physicians to an even greater extent and to significantly grow our company."

 

For the year ended December 31, 2011, Epocrates' revenue increased 9.0% to $113.3 million compared to $104.0 million for the year ended December 31, 2010. Epocrates' revenue totaled $29.7 million in the fourth quarter of 2011 compared to $30.3 million in the same quarter of the prior year, a decrease of 1.9%.

 

For the year ended December 31, 2011, net loss was $3.6 million compared to net income of $3.8 million in 2010. On a dilutive basis, net loss attributable to common stockholders was $3.9 million, or $0.17 per diluted share, compared to net income attributable to common stockholders of $0.1 million, or $0.01 per diluted share, for the same period in 2010. For the fourth quarter ended December 31, 2011, net loss was $6.5 million compared to net income of $2.7 million in the same quarter of the prior year. On a dilutive basis, net loss attributable to common stockholders was $6.5 million or $0.27 per diluted share compared to net income of $0.8 million or $0.09 per diluted share in the previous fourth quarter. The decrease in GAAP and non‐GAAP net income for the year to date and for the fourth quarter of 2011 was primarily attributable to the impairment of long‐lived assets and goodwill associated with the EHR offering. Net (loss) income attributable to common stockholders is calculated as net (loss) income less the preferred stock dividend that was due to Epocrates' preferred stockholders less an allocation of any remaining net income to the preferred stockholders. Upon completion of the company's initial public offering of its common stock, the preferred stock was converted to common stock.

 

Epocrates' adjusted EBITDA, as defined in the GAAP to non‐GAAP reconciliation provided later in this release, was $13.2 million, or 12% of revenue, for the year ended December 31, 2011 compared to $17.6 million, or 17% of revenue for the same period in 2010. Adjusted EBITDA was $3.1 million, or 11% of revenue, for the fourth quarter of 2011, compared to $7.1 million, or 23% of revenue, in the same period last year. The decline in adjusted EBITDA for the year to date and for the fourth quarter of 2011 was primarily attributable to the decrease in gross margin and operating expenses excluding the changes in non‐recurring and non‐cash items.

 

Cash, cash equivalents and short‐term investments totaled $85.2 million as of December 31, 2011.

Brandt concluded, "Epocrates' success this year will be defined by our ability to realize the full potential of our physician network – more than 340,000 strong. Our primary focus will be to strengthen our position of trust with physicians, based on value, which in turn will drive enhanced commercialization opportunities for our business."

 

Outlook for Full Year 2012


Epocrates expects full year 2012 revenue to be in the range of $105 million to $115 million, representing a decrease of 7% to an increase of 1.5% over full year 2011.

 

Earnings Call Information

 

Epocrates will host a conference call today beginning at 5:00 p.m. ET to discuss its strategic realignment, fourth quarter and full year 2011 results, followed by a question and answer session.

 

To participate in Epocrates' live conference call and webcast, please dial (877) 398‐9481 (domestic) or (760) 298‐5095 (international) using conference code 44991959, or visit http://investor.epocrates.com . A replay of the call will be available at the same address.

 

About Epocrates, Inc.

Epocrates, Inc. (NASDAQ: EPOC) is a leading physician platform for essential clinical content, practice tools and health industry engagement at the point of care. The Epocrates network consists of well over one million healthcare professionals, including approximately 340,000, or more than 50 percent of, U.S. physicians, who routinely use its solutions and services. Epocrates' portfolio includes top‐ranked medical apps, such as the industry's #1 most used


Forward‐Looking Statements


Statements contained in this press release under the heading "Outlook for Full Year 2012" and in Mr. Brandt's quotes regarding the company's ability to expand its business are forward‐ looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "potential," "will" and "expects" identify statements as forward‐looking statements. Forward‐looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Epocrates' actual results to be materially different than those expressed in or implied by Epocrates' forward‐looking statements. For Epocrates, particular uncertainties and risks include, among others: unexpected delays in delivering new products may occur, the company's inability to expand its physician network at the rate it expects, and lack of market acceptance of new products, which could cause Epocrates' revenues to be lower than expected. Additionally, the impact of competitive products and pricing may decrease demand for Epocrates's products and/or force Epocrates to decrease the price of its products, which would reduce its revenues. More detailed information on these and additional factors that could affect Epocrates' actual results are described in Epocrates' filings with the Securities and Exchange Commission, including its Annual Report on Form 10‐K filed with the Securities and Exchange Commission on March 31, 2011 under the heading "Risk Factors." Except as required by law, Epocrates undertakes no obligation to publicly update its forward‐looking statements.


Use of Non‐GAAP Financial Measures


To supplement Epocrates' consolidated financial statements presented on a U.S. generally accepted accounting principles (GAAP) basis, Epocrates uses non‐GAAP measures of adjusted EBITDA, gross profit, gross margin, net income and net income per share, which are adjusted to exclude certain costs, expenses, gains and losses Epocrates believes are appropriate to enhance an overall understanding of its past and future financial performance. These adjustments to current period GAAP results are made with the intent of providing both management and investors a more complete understanding of Epocrates' underlying operational results and trends and its marketplace performance. In addition, these adjusted non‐GAAP results are among the information management uses as a basis for planning and forecasting of future periods. The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with U.S. GAAP.

 

Adjusted EBITDA is not a measure of liquidity calculated in accordance with U.S. GAAP, and should be viewed as a supplement to—not a substitute for—results of operations presented on a GAAP basis. Adjusted EBITDA does not purport to represent cash flow provided by, or used in, operating activities as defined by GAAP. Epocrates' Consolidated Statements of Cash Flows presents its cash flow activity in accordance with GAAP. Furthermore, adjusted EBITDA is not necessarily comparable to similarly‐titled measures reported by other companies.

Epocrates believes adjusted EBITDA, adjusted net income, adjusted net income per share, adjusted gross profit and adjusted gross margin are used by and are useful to investors and other users of its financial statements in evaluating its operating performance because it provides them with additional tools to compare business performance across companies and across periods. Epocrates believes that:

 

  • EBITDA is widely used by investors to measure a company's operating performance without regard to such items as non‐recurring items, interest (income) expense, taxes, depreciation and amortization, which can vary substantially from company to company depending upon accounting methods and book value of assets, capital structure and the method by which assets were acquired;
  • investors commonly adjust EBITDA information to eliminate the effect of stock‐based compensation expenses and other charges, which can vary widely from company to company and impair comparability; and
  • adjusted net income, adjusted net income per share and adjusted gross profit/gross margin eliminate the effect of non‐recurring and non‐cash charges , which can vary widely from company to company and impair comparability year over year and across companies.

Epocrates management uses adjusted EBITDA, adjusted net income, adjusted net income per share, adjusted gross profit and adjusted gross margin:

 

  • as measures of operating performance to assist in comparing performance from period to period on a consistent basis;
  • as measures for planning and forecasting overall expectations and for evaluating actual results against such expectations;
  • in communications with the Board of Directors, stockholders, analysts and investors concerning our financial performance; and

Additionally, Epocrates management uses adjusted EBITDA as a significant performance measurement included in its bonus plan.

 

The tables that follow set forth a reconciliation of net (loss) income to adjusted net income and adjusted EBITDA. These tables also show a reconciliation of gross profit and gross margin from a GAAP to a non‐GAAP basis.

Media Contact

Holly Spring
athenahealth, Inc. (Media)
media@athenahealth.com
617-402-1631

Dana Quattrochi
athenahealth, Inc. (Investors)
investorrelations@athenahealth.com
617-402-1329

April Marks
Epocrates, Inc. (Media)
pr@epocrates.com
650-520-2413